A second set of variants results from 5ʹ splicing with a second promoter to generate truncated forms with only 6 transmembrane (6TM). While atypical in structure, these 6TM variants provide novel targets for compounds producing analgesia without many side effects. 7, 11 Levorphanol was developed and characterized before the classification of the standard opioid receptor families, 12, 13 the identification of their genes, [14] [15] [16] [17] [18] and the recognition of the importance of biased signaling in GPCR drug action. 19 While it is generally assumed that levorphanol acts through the traditional MOR-1, its subtle pharmacological differences from morphine suggest a more complex mechanism of action. It reportedly can interact with both N-methyl-d aspartate receptors and monoamine uptake function, 20 ,21 but at concentrations far greater than those needed for opioid receptor binding. The current study reexplores levorphanol in the context of our current understanding of µ opioid action.
METHODS Drugs
Morphine sulfate, levorphanol tartrate, and naloxone HCl were obtained from the Research Technology Branch of the National Institute on Drug Abuse (Rockville, MD). Naloxonazine 22 and IBNtxA (3-iodobenzoyl naltrexamine) 11 were synthesized in our laboratory as described previously and their structures were validated.
Animals. All animal studies were approved by the Institutional Animal Care and Use Committee of the Memorial Sloan Kettering Cancer Center and were conducted in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals in facilities accredited by the American Association for the Accreditation of Laboratory Animal Care. Animals were maintained on a 12-hour light/dark cycle with Purina rodent chow and water available ad libitum, and were housed in groups of 5 until testing. CD-1 mice were obtained from Charles River Laboratories (Wilmington, MA). Exon 11 MOR-1 knockout (KO) animals were generated by our laboratory as described previously, 23 and were backcrossed to a 129SvEv j background through speed congenic breeding (The Jackson Laboratory, Bar Harbor, ME). Double exon 1/exon 11 KO (E1/E11 KO) mice on a mixed 129SvEv-C57BL/6 background were generated as reported previously. 24 All in vivo testing of KO models used the corresponding background strain for comparison. Because the E1/E11 KO mice were not congenic, we used mixed background wild-type controls.
Lentivirus Production and Injection. Lentiviral constructs and lentivirus production were produced as described previously. 24 Briefly, the 6TM mMOR-1G cDNA was subcloned into a modified pWPI vector that independently expresses an enhanced green fluorescence protein (EGFP) (a gift from Dr Didier Trono, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland) to construct the lentimMOR-1G. Two lentiviruses, one expressing mMOR-1G and EGFP, and the other, expressing only EGFP (as a vector control), were generated in human embryonic kidney 293T cells by cotransfecting the lenti-mMOR-1G construct or pWPI vector with PAX2 (a packaging vector) and pMD2 (an envelope vector) using FuGENE HD transfection reagent (Promega, Madison, WI). The viral titer of the concentrated lentiviral particles was determined by quantifying EGFPexpressing cells in infected human embryonic kidney 293T cells with different dilutions using fluorescent microscopy. Two microliters of the lentiviral particles expressing mMOR-1G or vector alone without insertion (1.5 × 10 9 transducing units/mL) were administrated intrathecally or intracerebroventricularly in E11 KO or E1/E11 KO mice on days 1, 3, and 5 under general halothane anesthesia. Under these conditions, protein expression from the virus progressively increases over a month and then remains stable for at least 14 weeks. 24 All drug testing was performed between 5 and 14 weeks postviral injection.
Tail Flick Analgesia. Analgesia was assessed with the radiant heat tail flick assay using a Ugo Basile radiant heat tail flick machine (Varese, Italy) with baseline values between 2 and 3 seconds and a maximum latency of 10 seconds. ED 50 values (50% effective dose) were determined using a cumulative dose-response approach to measure tail flick latency after a radiant heat stimulus. 11 After baseline latency determinations, each animal was injected subcutaneously with escalating doses of drug and tested 30 minutes after the previous injection at peak effect. Tail flick latencies were converted to maximal percent effect (%MPE) by the formula %MPE = (observed latency − baseline latency)/(10 − baseline latency) × 100%. Dose-response curves were fit by nonlinear regression by GraphPad Prism (Carlsbad, CA). Dose-response curves were compared using an extra sumof-squares F test.
Gastrointestinal Motility Assay. Gastrointestinal transit was measured as described previously. 23 Briefly, animals (n = 6-7 per group) were injected with either saline or opioid, and 10 minutes later received a charcoal meal (10% charcoal and 2.5% gum tragacanth in distilled water) by gavage. Thirty minutes after administration of the charcoal meal, animals were killed by cervical dislocation, and the charcoal meal transit distance was measured and expressed as the total distance from the pyloric sphincter to the cecum.
Opioid Receptor Binding Assays.
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I-IBNtxA (0.1 nM) competition binding assays were performed in membranes prepared from Chinese Hamster Ovary (CHO) cells stably expressing the indicated mouse opioid receptor clones or from CD-1 mouse brain as described previously. 25, 26 Nonspecific binding was defined in the presence of levallorphan (8 μM), and was subtracted from total binding to yield specific binding. All points were determined in triplicate, and individual experiments independently replicated the indicated number of times. Inhibition curves for levorphanol were generated, the IC 50 (half-maximal inhibitory concentration) value was determined by nonlinear regression analysis, and K i values were calculated based on the Cheng/Prusoff conversion 27 using Prism (GraphPad, San Diego, CA). Protein concentrations were determined using the Lowry method.
homogenates from CHO cells stably transfected with mouse mu receptor (mMOR-1), delta receptor (mDOR-1), or kappa (mKOR-1) (50 µg protein) were incubated for 1 hour at 30°C with the indicated drug, 35 S-GTPγS (0.05 nM) and guanosine diphosphate (GDP) (60 µM in cell lines and 40 µM in brain) in a final volume of 1 mL assay buffer containing Tris HCl (50 mM; pH 7.4 at 37°C), MgCl 2 (3 mM), EGTA (ethylene glycol-bis(betaaminoethyl ether)-N,N,N',N'-tetraacetic) acid (0.2 mM), NaCl (100 mM), and a protease inhibitor cocktail (leupeptin, bestatin, aprotinin, and pepstatin). GDP concentrations were optimized for each receptor assay: DOR-1 and KOR-1, 10 µM; MOR-1, 30 µM; brain, 60 µM). Nonspecific binding was assessed by the addition of 10 µM cold GTPγS. Binding was terminated by vacuum filtration through Whatman GF/C glass fiber filters which were rinsed 3 × 2 mL with cold Tris HCl. Filters were cut out and 3 mL of scintillation fluor (Liquiscint, National Diagnostics, Atlanta, GA) was added to each tube and incubated at room temperature for at least 2 hours before being counted on a Packard Tri-Carb TR-2900 liquid scintillation counter.
β-Arrestin-2 Recruitment Assay. β-arrestin-2 recruitment was determined using the PathHunter enzyme complementation assay (DiscoveRx, Fremont, CA) using engineered CHO cells expressing the indicated engineered Oprm1 splice variant (DiscoveRx). 10 Cells were plated at a density of 2500 cells/well in a 384-well plate as described in the manufacturer protocol. The following day, cells were treated with the indicated compound for 90 minutes at 37°C followed by incubation with PathHunter detection reagents for 60 minutes. Chemiluminescence was measured with an Infinite M1000 Pro plate reader (Tecan, Männedorf, Switzerland).
Respiratory Depression
Respiratory rate was assessed in freely moving adult mice with the MouseOx pulse oximeter system (Starr Life Sciences, Oakmont, PA). 11 Mice were shaved around the neck 24 hours before testing and were habituated to the device for at least 1 hour before testing. A 5-second average breath rate was assessed at 5-minute intervals. A baseline was obtained over a 25-minute period before drug injection. Testing began 15 minutes after injection. Data are reported as percentage of baseline readings.
Statistical Analysis
Data analysis was performed using Prism (GraphPad). Behavioral dose-response curves were evaluated using nonlinear regression analysis to determine ED 50 values with 95% confidence limits. The model constrained the maximal response to 100% and the minimum response to 0% with a variable slope. Cumulative dose-response curves involved administering escalating doses of drug to each animal and testing the animal after each dose. The data were pooled and analyzed. In vitro studies examining 35 S-GTPγS binding and β-arrestin2 recruitment were evaluated using nonlinear regression analysis of doseresponse curves without constraints and a variable slope to determine EC 50 values with 95% confidence limits. In vitro studies utilized pooled data from 3 independent determinations. Receptor binding studies yielded IC 50 values based on the inhibition of control binding that was fit using nonlinear regression analysis with a model that constrained the maximal response to 100% and the minimum response to 0% with a variable slope. K i values were obtained based on the Cheng-Prusoff conversion. 27 Values are the means ± standard error of the mean of independent replications. Group comparisons utilized analysis of variance.
RESULTS

Levorphanol Effects on Opioid Receptors In Vitro
Levorphanol potently competed binding to the classical μ, δ, and κ receptors expressed in CHO cells (Table 1 ; Supplemental Digital Content, Figure 2 , http://links.lww. com/AA/C330). Its affinity was greatest for the full-length I-IBNtxA against the indicated variants stably expressed in Chinese Hamster Ovary cells, with the exception of the E11 site, which was determined in brain membranes in the presence of μ (DAMGO, 250 nM), δ (DPDPE, 250 nM), and κ 1 (U50,488H, 250 nM) blockers. Values represent the means ± standard error of the mean of at least 3 independent replications. Abbreviations: 6TM, 6 transmembrane; 7TM, 7 transmembrane. S-GTPγS binding was determined in Chinese Hamster Ovary cells stably expressing native MOR-1, DOR-1, or KOR-1 receptors and reported as stimulation over basal levels, as described in Methods. Full dose-response curves were performed for levorphanol. Results are from 3 pooled independent experiments. Levorphanol EC 50 values were determined using nonlinear regression analysis (Prism) and are the EC 50 and 95% confidence limits. Values for the internal standards (DAMGO, DPDPE, and U50,488H) are the means ± standard error of the mean for stimulation of these compounds at 1 µM in 3 independent experiments. For comparison, in similar experiments, morphine stimulated 35 S-GTPγS binding with and EC 50 of 42 ± 8 nM and a B max of 72% ± 9% DAMGO. (7TM) µ receptors, followed by δ and then κ (Table 1) . There was little difference in affinity for levorphanol among a series of full-length Oprm1 splice variants (Table 1) . Similar binding affinities were anticipated because they all share identical binding pockets comprised of the conserved transmembrane domains. 7 A second set of Oprm1 variants resulting from 5ʹ splicing are truncated, with only 6TM domains. 7,9 125 I-IBNtxA binding in brain membranes in the presence of blockers of traditional μ (DAMGO), δ (DPDPE), and κ (U50,488H) receptors labels a 6TM-dependent binding site. 11 Although classical opioids like morphine and methadone have no appreciable affinity for this target (K i >1000 nM), levorphanol competed it with a K i of 55 nM (Table 1) , similar to our prior observations. 11 Levorphanol was an agonist in 35 S-GTPγS binding assays against the classical opioid receptors ( Table 2 ; Supplemental Digital Content, Figure 3 , http://links.lww.com/AA/C330). Again, its potency was greatest against the µ receptor MOR-1, with lower potencies against DOR-1 and KOR-1. Against both MOR-1 and DOR-1, levorphanol elicited a full response when compared to a fixed concentration of DAMGO (1 µM) or DPDPE (1 µM), respectively. Against the κ receptor KOR-1, levorphanol was a partial agonist, stimulating binding only to a level approximately half that of U50,488H.
Recent study has revealed the importance of biased signaling in the actions of many drugs at GPCRs. 19, 28, 29 In the opioid field, morphine tolerance and respiratory depression were attenuated in a β-arrestin2 KO mouse. 30 We therefore examined levorphanol in parallel 35 S-GTPγS binding and β-arrestin2 recruitment assays 10 against several full-length Oprm1 variants (Table 3) . To assess β-arrestin2 recruitment, we utilized the PathHunter complementation assay (DiscoverX) in which 2 inactive fragments of β-galactosidase are fused to either the GPCR (ProLink tag, PK) or β-arrestin2 (enzyme acceptor). When β-arrestin2-enzyme acceptor attaches to the GPCR-PK β-galactosidase, activity from the fragments is restored, leading to cleavage of a reagent that induces chemiluminescence. The required fusion at the C-terminus of the GPCR with the ProLink tag did not significantly affect the binding affinity of the variants.
C-terminal splicing impacted levorphanol function in both 35 S-GTPγS and β-arrestin binding assays (Table 3 ; Supplemental Digital Content, Figure 4 , http://links.lww.com/AA/C330). Levorphanol potently stimulated 35 S-GTPγS binding with all the splice variants, but with differing efficacies. Furthermore, the relative variations in efficacy and potency did not co vary. Levorphanol was most efficacious against MOR-1A and MOR-1E, where stimulation was slightly greater than DAMGO control. Maximal levorphanol stimulation of 35 S-GTPγS binding was only slightly less against MOR-1 and MOR-1B1, with values that were quite similar despite 4-fold differences in their potency (ED 50 ). The largest differences were observed with MOR-1O. Here, levorphanol was a partial agonist, with maximal stimulation of only 70% that of DAMGO despite its very high potency.
Levorphanol stimulated β-arrestin2 recruitment far less effectively than 35 S-GTPγS binding. Compared to DAMGO, levorphanol was a partial agonist in the β-arrestin recruitment assays against all the variants, with EC 50 values higher than those for stimulating 35 S-GTPγS. Levorphanol was most efficacious against MOR-1, but even here, it only had a maximal recruitment equivalent to 30% that of DAMGO. It was even less efficacious against the other µ receptor splice variants, displaying a maximal response of <15% against MOR-1A and MOR-1B1. The differences between the 2 functional assays are readily seen with their dose-response curves (Supplemental Digital Content, Figure 4 , http:// links.lww.com/AA/C330). As with 35 S-GTPγS binding, potency did not correspond to efficacy.
Levorphanol Analgesia
Levorphanol was equally potent in CD-1 (ED 50 0.38 mg/kg) and 129 mice strains (ED 50 0.38 mg/kg; Figure 1A ) in the radiant heat tail flick assay and it was approximately 5-fold more potent than morphine (ED 50 2.3 mg/kg, subcutaneous [s.c.]) and oxycodone (ED 50 2.0 mg/kg, s.c.) in CD-1 mice. Levorphanol analgesia was dependent on mu opioid receptors as illustrated by its inactivity in a full Oprm1 KO mouse ( Figure 1B ). Increasing the dose to 100 mg/kg still failed to significantly increase tail flick latencies. Antagonist studies confirmed the importance of µ receptors ( Figure 1C ). Levorphanol analgesia was reversed by naloxone and levallorphan and the μ-selective antagonist β-funaltrexamine. The δ antagonist naltrindole 31 and the κ antagonist norbinaltorphimine 32 were ineffective at doses active against DPDPE and U50,488H, respectively. Naloxonazine is a μ-selective antagonist active against a subpopulation of mu opioid receptors. 22, 33, 34 As previously observed, naloxonazine completely blocked this dose of morphine. However, Stable cell lines expressing the indicated splice variant, engineered with the ProTag to enable testing in the β-arrestin2 PathHunter assay, were examined for levorphanol-induced stimulated 35 S-GTPγS binding as previously described or β-arrestin2 recruitment using the PathHunter assay from DiscoverX. 10 Full doseresponse curves were performed. Both EC 50 and B max values determined from 3 independent replications were pooled and analyzed by nonlinear regression analysis with Prism. Maximal effects are given relative to a fixed DAMGO concentration (1 µM). Results are presented, along with 95% confidence limits. Full dose-response curves are illustrated in Supplemental Digital Content, Figure 3 , http://links.lww.com/AA/C330. Bias factors were calculated as described previously. 10 Bias factors >0 imply G-protein bias, whereas those <0 suggest β-arrestin2 bias. For comparison, morphine has a bias factor of −1.5 at MOR-1 and of −5 at MOR-1O. naloxonazine only partially inhibited levorphanol analgesia, implying both sensitive and insensitive mechanisms and illustrating its differences from morphine.
Earlier study observed that levorphanol analgesia was partially sensitive to elimination of a set of truncated Oprm1 variants containing only 6TM in an E11 KO model. 11 In the present study, levorphanol analgesia (0.8 mg/kg, s.c.) was lower in the E11 KO mice ( Figure 1D ). Reconstituting expression of the E11-dependent variant MOR-1G through a lentiviral vector in the KO mouse restored analgesia, establishing a role for truncated 6TM variants in its analgesic actions. The Straub tail seen with levorphanol in wild-type mice remained intact in the E11 KO mice, consistent with a traditional 7TM receptor mechanism.
Cross tolerance is a measure of whether drugs share a common mechanism of action. Previous studies looking at morphine and levorphanol intravenous infusions in rats suggested that levorphanol displays incomplete cross tolerance to morphine. 4 In the current study, we examined groups of mice treated with levorphanol, morphine, or oxycodone for 4 days and assessed tolerance on the fifth day (Table 4) . Levorphanol was approximately 6-fold less potent after chronic administration while chronic morphine displayed a similar shift of 5.5-fold of its dose-response Figure 1 . Levorphanol analgesia. A, Analgesic activity in mouse strains: analgesic dose-response curves were determined in groups of CD-1 mice receiving levorphanol (n = 10-30), morphine (n = 20), or oxycodone (n = 10) at the indicated dose s.c., and were assessed for analgesia in the radiant heat tail flick assay 30 min later. ED 50 values with 95% confidence limits were determined by nonlinear regression analysis using GraphPad Prism: levorphanol, 0.38 mg/kg (0.28, 0.51); morphine, 2.2 mg/kg (1.4, 3.6); oxycodone, 2.0 mg/kg (1.3, 3.1). A group of 129/SvEv mice (n = 10) received levorphanol at the indicated dose and were assessed for analgesia in the radiant heat tail flick assay 30 min later, yielding an ED 50 0.38 (0.23, 0.64). B, Analgesic activity in a μ KO mouse: groups of mixed background wild-type (n = 9) or exon 1/exon 11 KO (E1/E11 KO) mice (n = 10) generated by heterozygous mating were administered levorphanol s.c., and assessed for analgesia in the radiant heat tail flick assay 30 min later. The dose-response curves were generated through a cumulative dosing paradigm. The ED 50 in the wild-type mice was 0.19 mg/kg (0.11, 0.31). C, Sensitivity of levorphanol analgesia to selective antagonists: groups of mice (n = 20) received saline, naloxone (1 mg/kg, s.c.), levallorphan (1 mg/kg, s.c.), or naltrindole (10 mg/kg, s.c.) 5 min before levorphanol (1 mg/kg, s.c.). Mice treated with norbinaltorphimine (norBNI) (20 mg/kg, s.c.), Funaltrexamine (β-FNA; 40 mg/kg, s.c.), or naloxonazine (35 mg/kg, s.c.) were given the antagonist 18-24 h before levorphanol. Groups of mice (n = 10) received saline or naloxonazine (35 mg/kg, s.c.) 18-24 h before morphine (3.5 mg/kg, s.c.). Analysis was carried using ANOVA followed by the Tukey multiple comparisons test. D, Rescue of levorphanol analgesia in an exon 11 MOR-1 KO: groups of wild-type C57/BL6 mice (n = 9), exon 11 KO mice on a C57/BL6 background (E11KO; n = 11), or exon 11 KO mice on a C57/BL6 background that had been administered a lentivirus containing mMOR-1G (E11KO/MOR-1G; n = 7) to reconstitute a 6 transmembrane (6TM) variant were administered levorphanol (0.8 mg/kg, s.c.) and assessed for analgesia in the radiant heat tail flick assay or for Straub tail. ANOVA revealed significant differences among the groups for analgesia (P < .0001; F 3,27 = 15.3). The Bonferroni multiple comparisons test revealed significant differences between wild-type and exon 11 KO mice (P < .0001) and between exon 11 KO mice with and without treatment with the lentivirus (P < .05). Wild-type mice and MOR-1G virus-treated exon 11 mice were not significantly different. The groups did not differ for the Straub tail, as determined by the Fisher exact test (WT versus E11KO, P = 1.0; WT versus E11KO/MOR-1G, P = .203; E11KO versus E11KO/MOR-1G, P = .240). ANOVA indicates analysis of variance; ED 50 , 50% effective dose; MPE, maximal percent effect; s.c., subcutaneous; WT, wild-type.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA Levorphanol Pharmacology curve. However, cross tolerance between the drugs was incomplete. Levorphanol analgesia was shifted only 3-fold in chronic morphine animals, compared to 5.5-fold for morphine. Similarly, both morphine and oxycodone showed only a 2-fold shift in the levorphanol-tolerant mice while levorphanol was shifted 6-fold.
Other Levorphanol Actions
Respiratory depression is a major safety issue with opioid use. We assessed respiratory function by measuring respiratory rate and administered both morphine and levorphanol at doses approximately 5-fold greater than their respective analgesic ED 50 values. As anticipated, morphine produced a profound decrease in respiratory rate of approximately 50% that persisted over the full length of observation (Figure 2A) . Although we observed a decrease in respiratory rate following levorphanol, it was not as great as morphine. Analyzing the areas under the curve for the 3 groups showed that morphine was significantly different from both saline (P < .001) and from levorphanol (P < .05) while the difference between saline and levorphanol did not reach statistical significance ( Figure 2B ).
Morphine and levorphanol both decreased gastrointestinal transit of a charcoal meal ( Figure 2C ). Both opioid treatments significantly depressed transit when compared to saline. The decrease from morphine and levorphanol at their analgesic ED 50 doses were comparable. Higher morphine doses typically totally inhibit transit in this assay. However, increasing the levorphanol dose 10-fold did not further reduce transit, implying a ceiling effect in its actions.
DISCUSSION
Not all μ opioids are the same and patients do not respond similarly to them. 35 Several mechanisms may be responsible for these subtle clinical differences. With biased signaling, 2 drugs acting through a common receptor may have different pharmacological profiles due to their differential activation of transduction pathways. 19 For example, 1 drug may preferentially activate G-protein transduction pathways while another may preferentially recruit β-arrestin2. With opioids, this can be important because β-arrestin2 has been implicated in many side effects, such as respiratory depression. 19, 30 The identification of a multitude of splice variants of the mu opioid receptor gene Oprm1 provides additional complexity because they provide multiple mu opioid receptor targets. Oprm1 generates dozens of distinct proteins through alternative splicing, with similar patterns in humans, mice, and rats (for review, see ref. 7) . These variants can be divided into 3 classes based on the protein structure. The majority , morphine (n = 4), or levorphanol (n = 5) after establishing a baseline and were monitored for 50 min. B, The area under the curves (AUCs) were determined for each treatment using Prism and compared using analysis of variance (ANOVA) followed by the Tukey multiple comparison test. The 3 groups were significantly different (F 2,10 = 16.64; P < .0007). Morphine was significantly different from both saline (P < .001) and levorphanol (P < .05). Levorphanol was not significantly different from saline. C, Inhibition of gastrointestinal transit: groups of mice (n = 9-10) received saline, morphine (3 mg/kg, s.c.), or levorphanol (0.4 or 4 mg/kg, s.c.). They then were given a charcoal meal and the distance traveled determined after 30 min, as described in methods. ANOVA showed that the groups were significantly different (F 3,35 = 34.8; P < .0001). The Tukey multiple comparison test showed that saline was significantly different from all the others (P < .001), but the morphine and levorphanol groups were not significantly different from each other.
are classical 7TM GPCRs with identical binding pockets defined by exons 1, 2, and 3 that differ only at the tip of the intracellular C-terminal. While drugs have similar receptor binding affinities of each of these variants, their efficacies and transduction bias varies from variant to variant and from drug to drug. 10 The overall pharmacological profile of a drug reflects the simultaneous activation of many splice variants with varying efficacies and bias, contributing to the variability in response among μ drugs.
In addition to the classical 7TM receptors, Oprm1 also generates a set of truncated proteins with 6TM that are an essential component of a novel binding site in brain and that also are involved with analgesia. 11, 24, 26, 36 The role of 6TM variants in μ opioid analgesia varies markedly among different drugs. For example, morphine analgesia is totally independent of these truncated forms, 23 but buprenorphine analgesia is lost in KO mice lacking them. 26 Levorphanol is an effective analgesic, with its relatively long half-life and activity against neuropathic pain being major advantages. 3 Although it acts through µ receptors, its actions subtly differ from morphine, as illustrated by their unidirectional cross tolerance in rats. 4, 5 Like other μ opioids, levorphanol labels the fulllength mu opioid receptors with similar low nanomolar affinities, while also showing affinity for δ and κ receptors and the 6TM-dependent 125 I-IBNtxA binding site in brain. It was a full agonist in 35 S-GTPγS binding studies at the classical μ (MOR-1) and δ receptors and a partial agonist at κ ones. However, its 35 S-GFTPγS activity profile varied among the µ receptor spice variants. Its ED 50 for MOR-1 was about 30-fold higher than MOR-1E and MOR-1O. It also failed to fully stimulate binding in the MOR-1O (69% DAMGO) compared to approximately 110% for MOR-1 and MOR-1E. This partial agonism of levorphanol at MOR-1O was similar to morphine (64% DAMGO), but quite different from fentanyl (110% DAMGO). 10 Among the full-length mu opioid receptor variants, levorphanol transduction showed a pronounced G-protein preference with markedly lower potency and maximal stimulation of β-arrestin compared to DAMGO. Its greatest β-arrestin response was only 30% that of DAMGO with MOR-1 and 10%-20% for the others. This preference for G-protein stimulation was consistent with its effects on respiratory rate. Many μ side effects have been associated with β-arrestin activity, 30, 37 including respiratory depression. 38 Although levorphanol depressed the respiratory rate, its effects were significantly lower than those of an equianalgesic morphine dose.
Levorphanol analgesia is dependent on mu opioid receptors. Elimination of all Oprm1 gene products in the E1/E11 KO animals blocked levorphanol analgesia. The small residual effect in the E1/E11 KO mice remained <15% MPE at doses as high as 250-fold greater than its analgesic ED 50 and is unlikely to be clinically relevant. However, the almost total dependence of levorphanol on Oprm1 gene products does not rule out a potential contribution from δ or κ receptors, although the antagonist studies make a δ or κ contribution less likely. The μ-selective antagonist β-funaltrexamine fully blocked levorphanol analgesia while neither the κ antagonist norbinaltorphimine nor the δ antagonist naltrindole were effective.
Despite its μ classification, levorphanol actions could be distinguished from morphine. The possibility of mechanistic differences between the 2 drugs was suggested a number of years ago by their unidirectional cross tolerance in the rat. 4 In these studies, rats tolerant to levorphanol showed cross tolerance to morphine while morphine-tolerant rats still responded to levorphanol. This suggested that, in addition to a shared target with morphine, levorphanol may also be acting through a second target not utilized by morphine. The incomplete cross tolerance between levorphanol and both morphine and oxycodone in the current study in mice supports this concept. Animals tolerant to 1 drug were only partially cross tolerant to the other. While the cross tolerance studies between levorphanol and morphine in both mice and rats were consistent with subtly different analgesic mechanisms, the mice showed bidirectional incomplete cross tolerance while rats displayed unidirectional cross tolerance. This difference could be due to a variety of reasons. In addition to potential species differences, the methodology also differed. Whereas the current study was performed over 5 days with intermittent subcutaneous dosing, the earlier rat report used continues intravenous infusions over 24 hours, resulting in a smaller degree of tolerance.
Unlike β-funaltrexamine, which antagonizes all µ receptor actions, naloxonazine antagonizes a restricted a subset of µ receptors and morphine actions. 22, 39 Naloxonazine fully blocked morphine analgesia but was only partially effective against an equianalgesic levorphanol dose. Levorphanol and morphine actions also could be differentiated genetically. Eliminating 6TM variants in the E11 KO mice modestly lowered levorphanol responses, a response that was rescued by reexpressing the 6TM variant MOR-1G using a lentiviral vector. In contrast, morphine analgesia was fully retained in the E11 KO mice. 23 However, the identity of this secondary target is still uncertain.
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I-IBNtxA labels a 6TM-dependent binding site in brain unrelated to traditional full-length μ, δ, or κ receptors that can mediate analgesia that is insensitive to norbinaltorphimine or to naltrindole 11, 24 that may contribute to levorphanol actions.
The current studies addressed the potential role of opioid receptors, but levorphanol also reportedly will interact with nonopioid systems. 6, 20, 21 It binds to NMDA receptors with a K i 600 nM 21 and inhibits both norepinephrine (1.2 µM) and serotonin uptake (90 nM). 20 However, the importance of these interactions is unclear because they occur at concentrations 50-to 100-fold greater than those needed to occupy opioid receptors. In naïve patients, for whom the dose of drug is titrated for activity on opioid receptors, the responses are less likely to involve these extraopioid receptor effects, but they may become more prominent at the higher doses used in tolerant subjects. For example, the brain concentrations of levorphanol in tolerant mice were noted to be 4-fold greater than naïve mice. 40 In conclusion, levorphanol is a potent analgesic that is valuable in pain management. While its early classification as a μ opioid is appropriate, new insights into the Oprm1 gene and its products has revealed a previously unrecognized complexity that may be contributing to the subtle, but
